US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging - 21/11/24

Doi : 10.14283/jpad.2022.86 
Chelsea G. Cox 1, 5, , M.A. Davis 2, J.D. Grill 3, 4, J.S. Roberts 1
1 Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, USA 
2 Department of Systems, Populations and Leadership, University of Michigan School of Nursing, Ann Arbor, MI, USA 
3 Department of Psychiatry and Human Behavior, University of California, Irvine School of Medicine, Irvine, CA, USA 
4 Department of Neurobiology and Behavior, University of California, Irvine School of Biological Sciences, Irvine, CA, USA 
5 1415 Washington Heights, 48109-2029, Ann Arbor, MI, USA 

a chelseak@umich.edu chelseak@umich.edu

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Recruitment to dementia prevention clinical trials is challenging, and participants are not representative of US adults at risk. A better understanding of the general public’s interest in dementia prevention research participation is needed to inform future recruitment strategies.

Objective

To examine US adults’ characteristics associated with self-reported likelihood to participate in dementia prevention clinical trials.

Design

We conducted a cross-sectional survey using the October 2018 wave of the University of Michigan National Poll on Healthy Aging.

Setting

The National Poll on Healthy Aging is a nationally representative survey of adults using KnowledgePanel (Ipsos Public Affairs LLC), a probability-based panel of the civilian, noninstitutionalized US population.

Participants

We analyzed data from 1,028 respondents, ages 50 to 64 years, who completed a web survey module on brain health.

Measurements

We used logistic regression models to examine associations between sociodemographic and dementia-related factors (e.g., family history) and self-reported likelihood to participate in a dementia prevention clinical trial of a new medicine (“very” or “somewhat likely” vs. “not likely” survey responses). Among respondents not likely to participate, we examined frequency of reasons endorsed for this decision, stratified by age, sex, and race and ethnicity.

Results

Of the 1,028 respondents, half were female, 68% Non-Hispanic White, 13% Hispanic, and 12% Non-Hispanic Black. Twelve percent of respondents reported being very likely to participate in a dementia prevention trial, 32% somewhat likely, and 56% not likely. Factors associated with higher likelihood to participate were higher perceived risk of dementia [OR, 2.17 (95% CI, 1.61, 2.93)], a positive family history of dementia [OR, 1.75 (95% CI, 1.27, 2.43)], and having discussed dementia prevention with a doctor [OR, 2.20 (95% CI, 1.10, 4.42)]. There were no differences in likelihood to participate by sociodemographic characteristics. Among 570 respondents not likely to participate, 39% said they did not want to be a guinea pig, 23% thought dementia would not affect them, 22% thought there would be too high a chance for harm, 15% indicated study participation would take too much time, and 5% reported fear of learning information about oneself. There were no differences across age, sex, and racial and ethnic groups.

Conclusions

In this study, perceived risk of dementia, family history, and discussion of prevention with a doctor were associated with likelihood to participate in a dementia prevention clinical trial, whereas sociodemographic factors including race and ethnicity were not. Findings suggest that recruitment interventions focused on increasing knowledge of dementia risk and prevention trials and involving healthcare providers may be effective tools to improve enrollment rates, regardless of target community.

El texto completo de este artículo está disponible en PDF.

Key words : Prevention, clinical trials, recruitment


Esquema


 Conflict of interest
The authors report no conflicts of interest.


© 2022  THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 10 - N° 1

P. 34-40 - janvier 2023 Regresar al número
Artículo precedente Artículo precedente
  • Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients
  • Cheng Fang, P. Hernandez, K. Liow, E. Damiano, H. Zetterberg, K. Blennow, D. Feng, M. Chen, M. Maccecchini
| Artículo siguiente Artículo siguiente
  • The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer’s Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
  • Edmond Teng, P.T. Manser, M. Shah, K. Pickthorn, N. Hu, S. Djakovic, H. Swendsen, M. Blendstrup, G. Faccin, S. Ostrowitzki, K.M. Sink

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.